SCHEMBL4479255

SCHEMBL4479255

COc1cc2c(Oc3ccc(Nc4ccc(C(C)(C)C)cc4)cc3)ccnc2cc1OCC1CCCN(C)C1

nearest known ligand 0.69

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 18/20 0.69
PDGFRA P16234 3/20 0.60
KIT P10721 2/20 0.60
PDGFRB P09619 1/20 0.60
KDR P35968 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4472055 0.89 FGFR2 (0.69) FGFR2PDGFRAKITPDGFRBKDR
SCHEMBL4470918 0.87 FGFR2 (0.76) FGFR2PDGFRAKITPDGFRBKDR
SCHEMBL4483005 0.86 FGFR2 (0.70) FGFR2PDGFRAKITPDGFRBKDR
SCHEMBL4469123 0.86 FGFR2 (0.72) FGFR2PDGFRAKITPDGFRBKDR
SCHEMBL4467873 0.85 FGFR2 (0.73) FGFR2PDGFRAKITPDGFRBKDR
SCHEMBL4470089 0.83 FGFR2 (0.85) FGFR2PDGFRAKITPDGFRBKDR
SCHEMBL4469764 0.83 FGFR2 (0.90) FGFR2PDGFRAKITPDGFRBKDR
SCHEMBL4472020 0.83 FGFR2 (1.00) FGFR2PDGFRAKITPDGFRBKDR
SCHEMBL13936676 0.83 FGFR2 (0.81) FGFR2PDGFRAKITPDGFRBKDR
SCHEMBL4473572 0.82 FGFR2 (0.84) FGFR2PDGFRAKITPDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 FGFR2 2/4885PDGFRA 372/4885KIT 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.